The effects of oral almitrine bismesylate, a respiratory stimulant that acts on peripheral arterial chemoreceptors, was studied in patients with chronic obstructive airways disease and hypoxaemic cor pulmonale. Twenty three patients admitted to hospital with an acute exacerbation of ventilatory failure were randomised to receive either almitrine 100 mg twice a day reducing to 50 mg twice a day over 48 hours or placebo in addition to conventional treatment. On admission the mean (SE) values for blood gas tensions were Pao2 4-8 (0-3) and Paco2 7-7 (0-3) kPa in the 12 patients who received almitrine and Pao2 49 (0-1) and Paco2 7-6 (0 3) kPa in the 11 who received placebo. After three hours of oxygen therapy at 1 1/min there was a similar rise in Pao2 in both groups, 6-4 (0 2) kPa in those receiving almitrine and 6-6 (0-4) kPa in those receiving placebo. After 24 hours of oxygen therapy values of PaO2 were again similar at 6-3 (0 8) kPa and 6-7 (2 2) kPa respectively. Arterial blood gas tensions improved during the study in those who survived but no significant differences were apparent between the two groups. There were six deaths, five in the almitrine group and one in the placebo group. There were no differences between the groups in respiratory rate, results of spirometry, oxygen requirement, or degree of dyspnoea (on visual analogue scale). The results did not show any benefit from oral almitrine in patients with acute respiratory failure secondary to chronic obstructive airways disease. Plasma almitrine concentrations, however, were often below the optimum therapeutic range, suggesting impaired drug absorption.
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Almitrine bismesylate is a recently developed respiratory stimulant that acts on peripheral chemoreceptors, principally of the carotid body, to increase tidal volume.' It also causes pulmonary vasoconstriction and may have beneficial effects on ventilation or perfusion matching within the lung.2 Oral almitrine 100-200 mg daily when taken for up to a year improves arterial blood gas tensions in patients with stable hypoxaemic chronic obstructive airways disease.3 Little information is available on the effect of the drug in patients with an acute exacerbation of chronic bronchitis and emphysema associated with acute ventilatory failure.
In theory almitrine, like other respiratory stimulants, would be an attractive means of reducing the requirement for oxygen and of limiting excessive hypercapnia during low flow oxygen therapy. It has the advantage that it can be taken orally. There is some evidence that intravenous almitrine can improve arterial oxygen tensions in patients with chronic obstructive airways disease and acute ventilatory failure,' but concern was expressed in one study because pulmonary artery pressure rose in all 12 patients, four of whom complained of malaise and increased dyspnoea.4 There are few studies of oral almitrine in patients with this condition and none has looked specifically at patients with hypoxaemic cor pulmonale. Patients with acute on chronic ventilatory failure given oral almitrine in a double blind study over two weeks did not show any improvement in blood gas tensions until day 10,' and in another study oral almitrine did not reduce the requirement for assisted ventilation. 8 Whether almitrine has a useful role in the treatment of acute ventilatory failure secondary to chronic obstructive airways disease has not been established clearly, and whether the drug is associated with a more rapid recovery or, more importantly, a reduction in the appreciable mortality associated with this condition is not known. We examined the effect of oral almitrine on arterial blood gas tensions, inspired oxygen requirement, symptoms, and survival in patients with acute respiratory failure and hypoxaemic cor pulmonale secondary to an exacerbation of chronic obstructive airways disease. (2 0) tension; FEV,-forced blood sample was taken to determine the plasma almitrine concentration and a further arterial sample taken. If the Paco2 had decreased or remained constant the inspired oxygen flow rate was increased to 1 5 1/min, if it had increased by less than 1 kPa the oxygen flow rate was left at 1 0 1/min, and if it had increased by more than 1 kPa the flow rate was reduced to 0 5 1/min. Blood was taken for estimation of the plasma almitrine concentration at five, eight, and 12 hours. Arterial blood gas tensions were rechecked again after 24 hours of treatment and as indicated clinically.
Methods

DRUG TREATMENT
Almitrine was given 100 mg twice daily with food for 24 hours followed by 100 mg in the morning and 50 mg in the evening for a further 24 hours and 50 mg twice daily with food for the next 18 days. Patients received chest physiotherapy twice daily and were not allowed to smoke. Fluid intake was initially restricted to 1 litre per day; the diuretics were continued for the duration of the trial. When the Pao2 had risen above 8 kPa for 24 hours the intravenous infusion of salbutamol was stopped and this drug was given by nebuliser (5 mg/5 ml four times a day). Antibiotic treatment was continued for 10 days. Other drug treatment on admission, including any corticosteroids, was continued unchanged.
MONITORING OF PATIENTS
The study was continued for three weeks. There were no significant differences in arterial blood gas tensions or oxygen flow rates.
After three hours of oxygen at 1 1/min the mean Pao2 had risen from 4-8 (0 3) to 6.4 (0 2) kPa in those receiving almitrine and from 4*9 (0 1) to 6-6 (04) kPa in those receiving placebo. After 24 hours of oxygen therapy mean values were 6 3 (0-8) kPa and 6-7 (2-2) kPa respectively. Figure 1 shows the mean changes in both Pao2 and Paco2 from baseline over time.
Arterial blood gas tensions improved during the study and after three weeks mean arterial blood gas tensions when patients were breathing air were Pao2 7-1 (0-83) kPa, Paco2 6-0 (0-5) kPa (n = 7) in those receiving almitrine and Pao2 8 1 (0 5) kPa, Paco2 6-5 (0-5) kPa (n = 10) in those receiving placebo. Figure 2 gives the mean FEV1, FVC, and respiratory rate and figure 3 gives the mean visual analogue scores for breathlessness and wellbeing. There were no significant differences between the two groups for any of these measurements. Table 3 gives the mean plasma almitrine concentrations in those receiving the drug. For the present this drug is better suited to the treatment of chronic than of acute respiratory failure.
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